Genomadix develops molecular tests, including FDA-cleared CYP2C19 genotyping, to facilitate genotype-guided dual antiplatelet therapy for stroke and TIA patients, thereby reducing the risk of recurrent ischemic events. The company also offers testing for Legionella and APOE, addressing critical needs in infectious disease management and precision medicine.
Funding
$5.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MCFounders
Product
Problem
Delayed or inaccurate CYP2C19 genotyping can hinder the effectiveness of dual antiplatelet therapy (DAPT) for stroke and TIA patients, increasing the risk of recurrent ischemic events due to the variable response to clopidogrel. Traditional CYP2C19 testing methods can be time-consuming, delaying the implementation of genotype-guided DAPT. Rapid and accurate testing is also needed for effective Legionella detection and APOE analysis.
Solution
Genomadix provides rapid, molecular diagnostic solutions, including the Genomadix Cube system, to enable timely and informed clinical decisions. The FDA-cleared Genomadix Cube CYP2C19 test delivers results within one hour, facilitating genotype-guided DAPT to minimize recurrent stroke risk. The company's portfolio also includes tests for Legionella and APOE, addressing critical needs in infectious disease management and precision medicine. The Genomadix Cube system enables testing where and when it is needed.
Target Audience
The primary target audience includes hospitals, stroke centers, and clinical laboratories seeking rapid and accurate molecular diagnostic tools for precision medicine and infectious disease management.
Features
- Rapid CYP2C19 genotyping with results available in one hour
- FDA 510(k)-cleared and CE Marked CYP2C19 test
- Genomadix Cube system for CYP2C19, Legionella, and APOE testing
- Molecular tests designed for point-of-care or near-patient use
- Aids in genotype-guided dual antiplatelet therapy (DAPT)
- APOE testing available for research use
- Legionella testing for environmental and water samples